Mostrar el registro sencillo del ítem
dc.contributor.author | Boerstra, Brittany A. | es_ES |
dc.contributor.author | Boenink, Rianne | es_ES |
dc.contributor.author | Astley, Megan E. | es_ES |
dc.contributor.author | Bonthuis, Marjolein | es_ES |
dc.contributor.author | ElHafeez, Samar Abd | es_ES |
dc.contributor.author | Arribas Monzón, Federico | es_ES |
dc.contributor.author | Asberg, Anders | es_ES |
dc.contributor.author | Beckerman, Pazit | es_ES |
dc.contributor.author | Bell, Samira | es_ES |
dc.contributor.author | Cases Amenós, Aleix | es_ES |
dc.contributor.author | Castro de la Nuez, Pablo | es_ES |
dc.contributor.author | ten Dam, Marc A.G.J. | es_ES |
dc.contributor.author | Debska-Slizien, Alicja | es_ES |
dc.contributor.author | Gjorgjievski, Nikola | es_ES |
dc.contributor.author | Giudotti, Rebecca | es_ES |
dc.contributor.author | Rodríguez Arévalo, Olga Lucía | es_ES |
dc.date.accessioned | 2024-04-24T18:06:03Z | |
dc.date.available | 2024-04-24T18:06:03Z | |
dc.date.issued | 2024-02-01 | es_ES |
dc.identifier.issn | 2048-8505 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/203716 | |
dc.description.abstract | [EN] Background The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD). This paper is a summary of the ERA Registry Annual Report 2021, including a comparison across treatment modalities.Methods Data was collected from 54 national and regional registries from 36 countries, of which 35 registries from 18 countries contributed individual patient data and 19 registries from 19 countries contributed aggregated data. Using this data, incidence and prevalence of KRT, kidney transplantation rates, survival probabilities and expected remaining lifetimes were calculated.Result In 2021, 533.2 million people in the general population were covered by the ERA Registry. The incidence of KRT was 145 per million population (pmp). In incident patients, 55% were 65 years or older, 64% were male, and the most common primary renal disease (PRD) was diabetes (22%). The prevalence of KRT was 1040 pmp. In prevalent patients, 47% were 65 years or older, 62% were male, and the most common PRDs were diabetes and glomerulonephritis/sclerosis (both 16%). On 31 December 2021, 56% of patients received haemodialysis, 5% received peritoneal dialysis, and 39% were living with a functioning graft. The kidney transplantation rate in 2021 was 37 pmp, a majority coming from deceased donors (66%). For patients initiating KRT between 2012-2016, 5-year survival probability was 52%. Compared to the general population, life expectancy was 65% and 68% shorter for males and females receiving dialysis, and 40% and 43% shorter for males and females living with a functioning graft. | es_ES |
dc.description.sponsorship | The ERA Registry is funded by the European Renal Association (ERA). This article was written by B.A. Boerstra <EM>et al.</EM> on behalf of the ERA Registry, which is an official body of the ERA. P.B. reports payments from AstraZeneca and Takeda. S.B. reports consulting fees from GSK, Bayer, and AstraZeneca. A.C.A. reports payments from Diaverum Spain. F.J. reports payments from AstraZeneca, Boehringer Ingelheim, Servier, and Merck; and support for attending meetings and/or travel from Servier, AstraZeneca, Pfizer, and Fresenius. J.M. reports receiving support for attending meetings and/or travel from CSL Vifor. M.F.S.-R. reports receiving consulting fees from Baxter, Fresenius, and Nipro; payments from Baxter and Fresenius; and support for attending meetings and/or travel from Vifor, Fresenius, and Palex. I.Z. reports consulting fees from Astellas, Pharma, and Bayer; and payments from AstraZeneca, Bayer, Behringer Ingelheim, Norameda, and Swixx Biopharma. A.O. reports receiving grants from Sanofi; and consultancy or speaker fees or travel support from Advicciene, Astellas Pharma, AstraZeneca, Amicus, Amgen, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Menarini, Mundipharma, Kyowa Kirin, Lilly, Alexion, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex, and Vifor Fresenius Medical Care Renal Pharma. K.J.J. reports receiving funds from ERA during the conduct of the study and grants from ESPN. V.S.S. reports receiving funds from ERA. | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.relation.ispartof | Clinical Kidney Journal. | es_ES |
dc.rights | Reconocimiento - No comercial (by-nc) | es_ES |
dc.subject | Dialysis | es_ES |
dc.subject | ESKD | es_ES |
dc.subject | Graft survival | es_ES |
dc.subject | Kidney transplantation | es_ES |
dc.subject | Patient survival | es_ES |
dc.title | The ERA Registry Annual Report 2021: a summary | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1093/ckj/sfad281 | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.description.bibliographicCitation | Boerstra, BA.; Boenink, R.; Astley, ME.; Bonthuis, M.; Elhafeez, SA.; Arribas Monzón, F.; Asberg, A.... (2024). The ERA Registry Annual Report 2021: a summary. Clinical Kidney Journal. 17(2). https://doi.org/10.1093/ckj/sfad281 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1093/ckj/sfad281 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 17 | es_ES |
dc.description.issue | 2 | es_ES |
dc.identifier.pmid | 38638342 | es_ES |
dc.identifier.pmcid | PMC11024806 | es_ES |
dc.relation.pasarela | S\513703 | es_ES |
dc.contributor.funder | European Renal Association-European Dialysis and Transplant Association | es_ES |